

## **Temozolomide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
10.1	26.09.2023	27573-00023	Date of first issue: 03.11.2014

#### SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name		Temozolomide Injection Formulation		
Manufacturer or supplier's o	leta	nils		
Company name of supplier	:	MSD		
Address	:	126 E. Lincoln Avenue		
		Rahway, New Jersey U.S.A. 07065		
Telephone	:	908-740-4000		
Emergency telephone	:	1-908-423-6000		
E-mail address	:	EHSDATASTEWARD@msd.com		
Recommended use of the chemical and restrictions on use				
Recommended use	:	Pharmaceutical		
Restrictions on use	:	Not applicable		

### **SECTION 2. HAZARDS IDENTIFICATION**

GHS Classification		Coloron 2
Acute toxicity (Oral)	·	Category 3
Serious eye damage/eye irritation	:	Category 2A
Germ cell mutagenicity	:	Category 2
Carcinogenicity	:	Category 2
Reproductive toxicity	:	Category 1B
Specific target organ toxicity - repeated exposure (Oral)	:	Category 1 (Bone marrow, thymus gland, Lymph nodes, spleen)

#### **GHS** label elements

Hazard pictograms	:	
Signal Word	:	Danger
Hazard Statements	:	<ul> <li>H301 Toxic if swallowed.</li> <li>H319 Causes serious eye irritation.</li> <li>H341 Suspected of causing genetic defects.</li> <li>H351 Suspected of causing cancer.</li> <li>H360FD May damage fertility. May damage the unborn child.</li> <li>H372 Causes damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.</li> </ul>
Precautionary Statements	:	Prevention:



## **Temozolomide Injection Formulation**

/ersion 0.1	Revision Date: 26.09.2023	SDS Number: 27573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
		P202 Do not h and understoc P260 Do not b P264 Wash sk P270 Do not e	breathe dust. kin thoroughly after handling. eat, drink or smoke when using this product. otective gloves/ protective clothing/ eye protection
		POISON CEN P305 + P351 - for several mir to do. Continu P308 + P313 I attention.	<ul> <li>+ P330 IF SWALLOWED: Immediately call a TER or doctor/ physician. Rinse mouth.</li> <li>+ P338 IF IN EYES: Rinse cautiously with water nutes. Remove contact lenses, if present and easy e rinsing.</li> <li>IF exposed or concerned: Get medical advice/ If eye irritation persists: Get medical advice/ atten-</li> </ul>
		<b>Storage:</b> P405 Store loo	cked up.
		<b>Disposal:</b> P501 Dispose posal plant.	of contents/ container to an approved waste dis-

#### Other hazards

Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Citric acid	77-92-9	>= 10 -< 20
Sodium chloride	7647-14-5	>= 10 -< 20
Temozolomide	85622-93-1	>= 5 -< 10

### SECTION 4. FIRST AID MEASURES

General advice	<ul> <li>In the case of accident or if you feel unwell, seek medical advice immediately.</li> <li>When symptoms persist or in all cases of doubt seek medical advice.</li> </ul>
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	<ul> <li>In case of contact, immediately flush skin with soap and plenty of water.</li> <li>Remove contaminated clothing and shoes.</li> <li>Get medical attention.</li> </ul>



# **Temozolomide Injection Formulation**

Version 10.1	Revision Date: 26.09.2023	SDS Number: 27573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
In case of eye contact		Thoroughly c In case of cou for at least 15 If easy to do, Get medical a	remove contact lens, if worn. attention.
If swallowed		Call a physici Rinse mouth	DO NOT induce vomiting. an or poison control center immediately. thoroughly with water. hything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed		: Toxic if swall Causes serio Suspected of Suspected of May damage Causes dama exposure if su	owed. us eye irritation. causing genetic defects. causing cancer. fertility. May damage the unborn child. age to organs through prolonged or repeated
Protect	tion of first-aiders	and use the r	onders should pay attention to self-protection, ecommended personal protective equipment ential for exposure exists (see section 8).
Notes t	to physician		matically and supportively.

### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Nitrogen oxides (NOx) Metal oxides Chlorine compounds
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :	Use personal protective equipment.
tive equipment and emer-	Follow safe handling advice (see section 7) and personal



# **Temozolomide Injection Formulation**

Version 10.1	Revision Date: 26.09.2023		DS Number: 573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014	
gency procedures			protective equipm	nent recommendations (see section 8).	
Environmental precautions		:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.		
Methods and materials for containment and cleaning up		:	container for disp Avoid dispersal or with compressed Dust deposits sho surfaces, as these released into the Local or national disposal of this m employed in the or determine which Sections 13 and	f dust in the air (i.e., clearing dust surfaces	

### SECTION 7. HANDLING AND STORAGE

Technical measures	<ul> <li>Static electricity may accumulate and ignite suspended dust causing an explosion.</li> <li>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.</li> </ul>
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	<ul> <li>Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.</li> </ul>
Hygiene measures	<ul> <li>Take care to prevent spills, waste and minimize release to the environment.</li> <li>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.</li> <li>When using do not eat, drink or smoke.</li> <li>Wash contaminated clothing before re-use.</li> </ul>
	The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures,



## **Temozolomide Injection Formulation**

Version 10.1	Revision Date: 26.09.2023	SDS Number: 27573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
Condi	tions for safe storage	use of administra : Keep in properly Store locked up. Keep tightly close	labeled containers.
Materi	ials to avoid	: Do not store with Strong oxidizing	the following product types: agents stances and mixtures

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m3 (OEB 5)	Internal
		Wipe limit	1 µg/100 cm2	Internal

Engineering measures	Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.	
Personal protective equipmer	t i i i i i i i i i i i i i i i i i i i	
Respiratory protection	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.	
Filter type Hand protection	Particulates type	
Material	Chemical-resistant gloves	
Remarks Eye protection	Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.	
Skin and body protection	Work uniform or laboratory coat.	



# **Temozolomide Injection Formulation**

Version 10.1	Revision Date: 26.09.2023		S Number: 573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
			task being perform disposable suits)	arments should be used based upon the ned (e.g., sleevelets, apron, gauntlets, to avoid exposed skin surfaces. legowning techniques to remove potentially hing.
SECTIC	N 9. PHYSICAL AND CHI	EMIC		6
Ар	bearance	:	powder	
Col	or	:	white	
Od	or	:	No data available	9
Od	or Threshold	:	No data available	9
pН		:	No data available	9
Me	Iting point/freezing point	:	No data available	9
Init ran	al boiling point and boiling ge	:	No data available	9
Fla	sh point	:	Not applicable	
Eva	aporation rate	:	Not applicable	
Fla	mmability (solid, gas)	:	May form explosi handling or other	ive dust-air mixture during processing, means.
Fla	mmability (liquids)	:	No data available	9
	per explosion limit / Upper nmability limit	:	No data available	9
	ver explosion limit / Lower nmability limit	:	No data available	9
Va	oor pressure	:	Not applicable	
Re	ative vapor density	:	Not applicable	
Re	ative density	:	No data available	9
De	nsity	:	No data available	2
	ubility(ies) Water solubility	:	soluble	
	tition coefficient: n- anol/water	:	Not applicable	
	anoi/water oignition temperature	:	No data available	9
De	composition temperature	:	No data available	9



## **Temozolomide Injection Formulation**

Version 10.1	Revision Date: 26.09.2023	SDS Number: 27573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
	sity scosity, kinematic sive properties	: Not applicab : Not explosive	
	zing properties cular weight	: The substand	ce or mixture is not classified as oxidizing. lable
Partic	le size	: No data avai	lable

### SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions		Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely rout Inhalation Skin contact Ingestion Eye contact	es of	exposure
Acute toxicity Toxic if swallowed.		
<u>Product:</u> Acute oral toxicity	:	Acute toxicity estimate: 241.75 mg/kg Method: Calculation method
Components:		
Citric acid:		
Acute oral toxicity	:	LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity

### Sodium chloride:



# **Temozolomide Injection Formulation**

Vers 10.1	ion	Revision Date: 26.09.2023		OS Number: 573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
	Acute o	oral toxicity	:	LD50 (Rat): 3,550	) mg/kg
	Acute i	nhalation toxicity	:	LC50 (Rat): > 42 Exposure time: 1 Test atmosphere:	h
	Acute o	dermal toxicity	:	LD50 (Rabbit): >	5,000 mg/kg
	Temoz	olomide:			
		oral toxicity	:	LD50 (Dog): 19 m	ıg/kg
				LD50 (Rat): 315 n	ng/kg
				LD50 (Mouse): 20	)5 mg/kg
		orrosion/irritation ssified based on availa	able	information.	
	Compo	onents:			
	Citric a	acid:			
	Specie Methoo		:	Rabbit OECD Test Guide	eline 404
	Result	-	:	No skin irritation	
	Sodiur	n chloride:			
	Specie	S	:	Rabbit	
	Result		:	No skin irritation	
		s eye damage/eye irr	itati	on	
		onents:			
	Citric a	acid:			
	Specie	S	:	Rabbit	
	Result Method	ł	:	Irritation to eyes, OECD Test Guide	reversing within 21 days eline 405
	Sodiur	n chloride:			
	Specie Result	S	:	Rabbit No eye irritation	
	Respir	atory or skin sensitiz	atio	n	
		ensitization ssified based on availa	able	information	
		atory sensitization	2010		

Not classified based on available information.



# **Temozolomide Injection Formulation**

ersion ).1	Revision Date: 26.09.2023	SDS Number: 27573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
<u>Comp</u>	onents:		
Test T	s of exposure es	: Local lymph : Skin contact : Mouse : negative	node assay (LLNA)
Test T	s of exposure es	: Maximizatior : Dermal : Guinea pig : negative	n Test
	cell mutagenicity		
•	ected of causing gene	etic defects.	
Citric	onents:		
	oxicity in vitro	: Test Type: B Result: nega	acterial reverse mutation assay (AMES) tive
		Test Type: ir Result: positi	n vitro micronucleus test ive
		Test Type: B Result: nega	acterial reverse mutation assay (AMES) tive
Genot	oxicity in vivo	cytogenetic t Species: Rat	Route: Ingestion
Sodiu	m chloride:		
Genot	oxicity in vitro	: Test Type: Ir Result: positi	n vitro mammalian cell gene mutation test ive
		Test Type: B Result: nega	acterial reverse mutation assay (AMES) tive
		Test Type: S (in vitro) Result: positi	accharomyces cerevisiae, gene mutation assay
			NA damage and repair, unscheduled DNA syn- nmalian cells (in vitro) ive
		Test Type: C Result: positi	hromosome aberration test in vitro



# **Temozolomide Injection Formulation**

sion 1	Revision Date: 26.09.2023		S Number: 573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
			Test Type: Ch Result: negativ	romosome aberration test in vitro re
Genot	oxicity in vivo	:	Species: Mous	
			Application Ro Result: negativ	ute: Intraperitoneal injection /e
				tagenicity (in vivo mammalian bone-marrow st, chromosomal analysis)
				ute: Intraperitoneal injection
	cell mutagenicity - sment	:	Weight of evid cell mutagen.	ence does not support classification as a ger
Temo	zolomide:			
Genot	oxicity in vitro	:	Test Type: Bae Result: positive	cterial reverse mutation assay (AMES)
				romosome aberration test in vitro luman lymphocytes ə
	cell mutagenicity - sment	:		s from in vitro mammalian mutagenicity assa ture activity relationship to known germ cell
Carci	nogenicity			
Suspe	ected of causing cancer	ſ.		
Comp	oonents:			
Sodiu	m chloride:			
Specie		:	Rat	
	ation Route		Ingestion 2 Years	
Resul		:	negative	
Temo	zolomide:			
Specie		:	Rat	
	ation Route	:	Oral	
Expos	sure time	:	6 Months	weight
Resul	t	·	4 mg/kg body positive	weight
	t Organs	:	Mammary glar	d
Carcir	nogenicity - Assess-	:	Limited eviden	ce of carcinogenicity in animal studies

May damage fertility. May damage the unborn child.



# **Temozolomide Injection Formulation**

sion 1	Revision Date: 26.09.2023		DS Number: 573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
Comp	<u>onents:</u>			
Citric				
Effects	s on fetal development	:	Test Type: One Species: Rat Application Rou Result: negative	
Temoz	zolomide:			
Effects	s on fertility	:	Species: Rat, m Application Rou	ute: Oral .: 8.5 mg/kg body weight
Effects	s on fetal development	:	Species: Rat Application Rou Embryo-fetal to	oryo-fetal development ute: Oral xicity.: LOAEL: 13 mg/kg body weight , Malformations were observed.
	ductive toxicity - As-		Clear evidence	of adverse effects on sexual function and
Reproo sessm	-	•		on animal experiments., Clear evidence of on development, based on animal
sessm STOT- Not cla	-	able	adverse effects experiments.	
sessm STOT- Not cla	ent -single exposure assified based on availa onents:	able	adverse effects experiments.	
sessm STOT- Not cla <u>Comp</u>	ent -single exposure assified based on availa onents: acid:	able :	adverse effects experiments.	
SESSM STOT- Not cla <u>Comp</u> Citric Assess	ent <b>single exposure</b> assified based on availa <u>onents:</u> acid: sment	i able :	adverse effects experiments.	on development, based on animal
SESSM STOT- Not cla Comp Citric Assess STOT- Cause	ent -single exposure assified based on availa onents: acid: sment -repeated exposure	: one	adverse effects experiments. information. May cause resp marrow, thymus	on development, based on animal
SESSM STOT- Not cla Comp Citric Assess STOT- Cause longed	ent -single exposure assified based on availa onents: acid: sment -repeated exposure s damage to organs (Be	: one	adverse effects experiments. information. May cause resp marrow, thymus	on development, based on animal
SESSM STOT- Not cla Comp Citric Assess STOT- Cause longed Comp	ent -single exposure assified based on availa <u>onents:</u> acid: sment -repeated exposure s damage to organs (Be or repeated exposure	: one	adverse effects experiments. information. May cause resp marrow, thymus	on development, based on animal
SESSM STOT- Not cla Comp Citric Assess STOT- Cause longed Comp Temoz Routes	ent -single exposure assified based on availa onents: acid: sment -repeated exposure s damage to organs (Bo or repeated exposure onents: zolomide: s of exposure Organs	: one	adverse effects experiments. information. May cause resp marrow, thymus vallowed. Ingestion Bone marrow, t	on development, based on animal biratory irritation. gland, Lymph nodes, spleen) through pro
SESSM STOT- Not cla Comp Citric Assess STOT- Cause longed Comp Temoz Routes Target Assess	ent -single exposure assified based on availa onents: acid: sment -repeated exposure s damage to organs (Bo or repeated exposure onents: zolomide: s of exposure Organs	: one	adverse effects experiments. information. May cause resp marrow, thymus vallowed. Ingestion Bone marrow, t Causes damag	on development, based on animal biratory irritation. gland, Lymph nodes, spleen) through pro
SESSM STOT- Not cla Comp Citric Assess STOT- Cause longed Comp Temoz Routes Target Assess Repea	ent -single exposure assified based on availa onents: acid: sment -repeated exposure s damage to organs (Be or repeated exposure onents: zolomide: s of exposure Organs sment	: one	adverse effects experiments. information. May cause resp marrow, thymus vallowed. Ingestion Bone marrow, t Causes damag	on development, based on animal biratory irritation. gland, Lymph nodes, spleen) through pro
SESSM STOT- Not cla Comp Citric Assess STOT- Cause longed Comp Temoz Routes Target Assess Repea	ent -single exposure assified based on availa onents: acid: sment -repeated exposure s damage to organs (Be or repeated exposure onents: zolomide: s of exposure Organs sment -ted dose toxicity onents: onents:	: one	adverse effects experiments. information. May cause resp marrow, thymus vallowed. Ingestion Bone marrow, t Causes damag	piratory irritation. gland, Lymph nodes, spleen) through pro



# **Temozolomide Injection Formulation**

rsion .1	Revision Date: 26.09.2023	SDS Number: 27573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014
LOAE	L	: 8,000 mg/k	g
Applic	ation Route	: Ingestion	
Expos	sure time	: 10 Days	
Sodiu	m chloride:		
Specie	es	: Rat	
LÒAE	L	: 2,533 mg/k	g
Applic	ation Route	: Ingestion	-
Expos	sure time	: 2 y	
Temo	zolomide:		
Specie	es	: Rat, female	
NOAE		: 4 mg/kg	
LOAE		: 21 mg/kg	
	ation Route	: Oral	
	sure time	: 6 Months	
Targe	t Organs	: Lymph nod organs	es, thymus gland, Bone marrow, Reproductive
Speci		: Rat, male	
NOAE		: 8.5 mg/kg	
LOAE		: 34 mg/kg	
	ation Route	: Oral	
	sure time t Organs	: 6 Months	es, thymus gland, Bone marrow, male reproduct
Targe	Ulgans		strointestinal tract
Specie	es	: Dog	
NOAE		: 2.5 mg/kg	
LOAE		: 6.3 mg/kg	
	ation Route	: Oral	
	sure time	: 6 Months	
Targe	t Organs		w, spleen, male reproductive organs, Gastrointe nymus gland
Aspir	ation toxicity		
•	assified based on av	ailable information.	
Exper	ience with human e	exposure	
<u>Comp</u>	onents:		
	zolomide:		
Ingest	ion		Blood disorders, Nausea, Vomiting, Diarrhea, atigue, hair loss
CTION	12. ECOLOGICAL II	NFORMATION	
		-	

## Components:

Citric acid:



# **Temozolomide Injection Formulation**

rsion .1	Revision Date: 26.09.2023		98 Number: 573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014	
Toxicity to fish		:	LC50 (Pimephales promelas (fathead minnow)): > 100 m Exposure time: 96 h		
Toxicity to daphnia and other aquatic invertebrates		:	EC50 (Daphnia magna (Water flea)): 1,535 mg/l Exposure time: 24 h		
Sodiu	ım chloride:				
Toxicity to fish		:	LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l Exposure time: 96 h		
Toxicity to daphnia and other aquatic invertebrates		:	EC50 (Daphnia magna (Water flea)): 4,136 mg/l Exposure time: 48 h		
Toxici plants	ty to algae/aquatic	:	EC50: > 2,000 mg Exposure time: 96		
Toxici icity)	ty to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 33	es promelas (fathead minnow)): 252 mg/l 3 d	
Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)		:	NOEC (Daphnia p Exposure time: 2 <sup>2</sup>	oulex (Water flea)): 314 mg/l 1 d	
	ity to microorganisms	:	EC10: > 1,000 mg	g/I	
Temo	zolomide:				
Toxici	ty to fish	:	LC50 (Oncorhync Exposure time: 96 Method: OECD T		
	ity to daphnia and other ic invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD T		
Toxici plants	ty to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD T		
			NOEC (Pseudokin mg/l Exposure time: 72 Method: OECD T		
Toxici	ty to microorganisms	:	EC50: > 100 mg/l Exposure time: 3 Test Type: Respir Method: OECD T	h ration inhibition	
Persi	stence and degradabili	ity			
Comr	onents:				

## Components:

### Citric acid:



## **Temozolomide Injection Formulation**

ersion 0.1	Revision Date: 26.09.2023	SDS Number: 27573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014			
Biodegradability		Biodegradat Exposure tin	Result: Readily biodegradable. Biodegradation: 97 % Exposure time: 28 d Method: OECD Test Guideline 301B			
	ozolomide:					
Biodegradability		: Result: rapic Biodegradat Exposure tin				
Stability in water		: Degradation	half life (DT50): < 1 d			
Bioad	ccumulative potentia	al				
<u>Comp</u>	oonents:					
Citric	acid:					
	ion coefficient: n- ol/water	: log Pow: -1.	72			
Temo	zolomide:					
	ion coefficient: n- ol/water	: log Pow: 1.3	5			
Mobi	lity in soil					
No da	ata available					
Other	r adverse effects					
No data available						

Disposal methods		
Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste
		handling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

#### **International Regulations**

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.



### Temozolomide Injection Formulation

Version 10.1	Revision Date: 26.09.2023	SDS Number: 27573-00023	Date of last issue: 20.03.2023 Date of first issue: 03.11.2014		
Dom	estic regulation				
	NOM-002-SCT Not regulated as a dangerous good				
Spec	Special precautions for user				
Not a	pplicable				
SECTION	15. REGULATORY I	NFORMATION			
	Safety, health and environmental regulations/legislation specific for the substance or mixture				
esser	Federal Law for the control of chemical precursors, : Not applicable essential chemical products and machinery for producing capsules, tablets and pills.				
The ingredients of this product are reported in the following inventories:					
AICS		: not determine	d		
DSL		: not determine	d		

# IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

Revision Date	:	26.09.2023
Date format	:	dd.mm.yyyy

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System: GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substanc-



### **Temozolomide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
10.1	26.09.2023	27573-00023	Date of first issue: 03.11.2014

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-
Data Sheet		cy, http://echa.europa.eu/

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8